Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Lisa Oneil

Internal Medicine Westland, MI Doctor of Osteopathy

NPI 1437252749 CMS profile 338045

33611 Warren Rd, Westland, MI 48185

Open in the dashboard

General payments

$4,066

237 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Lisa Oneil of Westland, MI is reported in the CMS Open Payments database as having received $4,066 across 237 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $222 12
2023 General $810 39
2022 General $753 43
2021 General $983 56
2020 General $709 42
2019 General $589 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Oneil
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Lisa Oneil were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Lisa Oneil Internal Medicine median Middle half National median
2019 $589 $159 $48–$570 $163
2020 $709 $119 $33–$402 $114
2021 $983 $135 $37–$521 $132
2022 $753 $141 $42–$496 $149
2023 $810 $149 $45–$519 $160
2024 $222 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $724 40 payments
  2. GlaxoSmithKline, LLC. $638 41 payments
  3. Lilly USA, LLC $460 26 payments
  4. AbbVie, Inc. $454 28 payments
  5. Janssen Pharmaceuticals, Inc $433 23 payments
  6. AstraZeneca Pharmaceuticals LP $349 24 payments
  7. Amgen Inc. $255 13 payments
  8. Pfizer Inc. $206 10 payments
  9. Novo Nordisk Inc $112 7 payments
  10. Dexcom, Inc. $99 5 payments
  11. Other $337 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $4,066 237 payments
Products named General payments · program years 2019–2024
  1. JARDIANCE Diabetes $442 24 payments
  2. TRELEGY ELLIPTA $423 25 payments
  3. XARELTO $400 22 payments
  4. GLYXAMBI $302 16 payments
  5. QULIPTA $282 18 payments
  6. TRULICITY $212 13 payments
  7. UBRELVY $209 12 payments
  8. JARDIANCE Diabetes $194 12 payments
  9. Prolia $184 10 payments
  10. EVENITY $171 9 payments
  11. Other $3,052 174 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,292

Median for Internal Medicine: 777

Drug cost

$51,280

Median for Internal Medicine: $73,373

Branded share of claims

11.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 13 $21,991
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 14 $12,353
Albuterol Sulfate Hfa Albuterol Sulfate Brand 40 $1,651
Atorvastatin Calcium Generic 129 $1,647
Levothyroxine Sodium Generic 97 $1,320
Amlodipine Besylate Generic 127 $990
Omeprazole Generic 69 $818
Pantoprazole Sodium Generic 40 $790
Gabapentin Generic 50 $749
Ketoconazole Generic 13 $732

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$9,584

Medicare's payments for the services billed

Medicare patients

61

Average age 74

Services billed

189

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 38%
COPD 33%
Ischemic heart disease 28%
Heart failure 26%
Chronic kidney disease 26%
Depression 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $33
$33 — —
ZEPBOUND
  • Lilly USA, LLC $32
$32 — —
UBRELVY
  • AbbVie, Inc. $28
$28 — —
QULIPTA
  • AbbVie, Inc. $28
$28 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record